Scarica l'app Stockscreener
168.76
1.84%
-3.17
Dopo l'orario di chiusura:
168.16
-0.60
-0.36%
Precedente Chiudi:
$171.93
Aprire:
$171.04
Volume 24 ore:
102.73K
Relative Volume:
0.54
Capitalizzazione di mercato:
$6.74B
Reddito:
-
Utile/perdita netta:
$-77.61M
Rapporto P/E:
-73.44
EPS:
-2.2979
Flusso di cassa netto:
-
1 W Prestazione:
-5.58%
1M Prestazione:
+2.83%
6M Prestazione:
+107.68%
1 anno Prestazione:
+186.62%
Intervallo 1D:
$167.00
$171.20
Intervallo di 1 settimana:
$167.00
$183.67
Portata 52W:
$53.59
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Nome
Belite Bio Inc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare BLTE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
168.76 | 6.87B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-26 | Iniziato | BofA Securities | Buy |
| 2026-01-06 | Iniziato | Morgan Stanley | Overweight |
| 2025-12-02 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-11-20 | Iniziato | Mizuho | Neutral |
| 2023-12-14 | Iniziato | Maxim Group | Buy |
| 2023-07-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Iniziato | SVB Securities | Outperform |
| 2022-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-01 | Iniziato | The Benchmark Company | Buy |
Mostra tutto
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Belite Bio CEO Lin Yu-Hsin sells $1.66m in shares - Investing.com India
Belite Bio (BLTE) CEO Lin Yu-Hsin sells 9,200 ADS in planned trade - Stock Titan
Belite Bio (BLTE) director sells 1,100 ADS via Rule 10b5-1 plan - Stock Titan
Belite Bio (BLTE) CFO sells 6,200 ADS under Rule 10b5-1 plan - Stock Titan
H.C. Wainwright reiterates Belite Bio stock rating at buy By Investing.com - Investing.com Australia
Belite Bio (BLTE) Eps Diluted (TTM) - Zacks Investment Research
BLTE (NASDAQ) files Form 144 listing ADS sales and vesting activity - Stock Titan
[144] BELITE BIO, INC SEC Filing - Stock Titan
Belite Bio (NASDAQ: BLTE) lists 1,400 and 8,796 shares from option exercises - Stock Titan
(BLTE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Benchmark reaffirms Belite Bio stock rating on cash position, trial progress - Investing.com Canada
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Belite Bio (NASDAQ:BLTE) Rating Increased to Hold at Wall Street Zen - Defense World
Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance - tipranks.com
Belite Bio (BLTE) Is Up 7.9% After Phase 3 DRAGON Win And $402M OfferingHas The Bull Case Changed? - Sahm
Mizuho reiterates Belite Bio stock rating on NDA timeline update - Investing.com
[Form 4] BELITE BIO, INC Insider Trading Activity - Stock Titan
Belite Bio (BLTE) CFO now holds 289,736 vested option shares - Stock Titan
Belite Bio (BLTE) CSO gains 144,868-share option vesting - Stock Titan
Belite Bio Jumps on Drug Hopes and Analyst Boost - TipRanks
Belite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk - TipRanks
Belite Bio, Inc. ADR Shares Surge on Drug Progress - tipranks.com
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website - The Manila Times
Belite Bio (NASDAQ: BLTE) posts 2025 Form 20-F and audited results online - Stock Titan
Belite Bio (BLTE) 2025 20-F: Tinlarebant NDA plan and rising losses - stocktitan.net
Stargardt Disease Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - Barchart.com
Short Interest in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Grows By 25.1% - MarketBeat
(BLTE) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Wall Street Zen - MarketBeat
Belite Bio (NASDAQ: BLTE) CMO details option grants and indirect holdings - Stock Titan
Belite Bio (NASDAQ: BLTE) CSO details stock options and share stakes - Stock Titan
Belite Bio (BLTE) CFO Chuang Hao-Yuan details options and shares in Form 3 - Stock Titan
Belite Bio (NASDAQ: BLTE) director discloses 400 ADS position - Stock Titan
BELITE BIO (BLTE) director Longo reports 110,000-share stock option holdings - Stock Titan
Belite Bio (BLTE) director Lu Ita reports 110,000-share option stake - Stock Titan
Belite Bio (BLTE) director details stock option grants and vesting - Stock Titan
Belite Bio (BLTE) CEO Lin Yu-Hsin details option and share holdings - Stock Titan
Belite Bio (BLTE) director reports initial ADS and ordinary share stakes - Stock Titan
(BLTE) Risk Channels and Responsive Allocation - Stock Traders Daily
Belite Bio Stock Stumbles as Traders Flee Rally - TipRanks
Short Interest in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Expands By 16.2% - MarketBeat
Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference - Defense World
Mizuho reiterates Belite Bio stock rating on NDA timeline update By Investing.com - Investing.com Nigeria
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright raises Belite Bio stock price target on NDA timeline - Investing.com Nigeria
Belite Bio Eyes 2027 Launch After Pivotal Win - TipRanks
Belite Bio at Leerink Conference: Tinlarebant’s Promising Trials - Investing.com
Belite Bio (BLTE) to Release Earnings on Monday - MarketBeat
What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World
Belite Bio Inc Adr Azioni (BLTE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):